Home Online Features New Investment from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) Leads Efforts to Develop Standardization Materials for Leading Diagnostic Biomarker
New Investment from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Leads Efforts to Develop Standardization Materials for Leading Diagnostic Biomarker
Press Releases
November 14, 2024

New Investment from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Leads Efforts to Develop Standardization Materials for Leading Diagnostic Biomarker

By Alzheimer's Drug Discovery Foundation

The DxA partners with Dr's Henrik Zetterberg and Nicholas Ashton to create critical standardized reference materials for leading Alzheimer's blood biomarker, p-Tau217, to ensure consistency across global research and clinical

bradford

The Bradford Era

email
Local & Social